Relationship Details

This document page appears to be a legal disclosure or risk factor description regarding 'pay-to-play' laws and SEC regulations. It outlines the risks associated with investment advisers making political contributions to elected officials, noting that such actions could prohibit the adviser from receiving compensation for two years and negatively impact 'the Fund.' The document bears a House Oversight Bates stamp, indicating it is part of a congressional investigation.

This document is page 58 of a confidential investment memorandum (Control Number 257) outlining 'Certain Investment Considerations' for a venture capital fund. The text details significant risks associated with the fund, specifically noting its focus on life sciences and healthcare technology, the lack of diversification, and the dependency on FDA approvals. It explicitly warns investors that they should be able to withstand a total loss of their investment.